Hologic and Boston Scientific, both headquartered in Marlborough, MA, are leading U.S. MedTech companies. Hologic focuses on women’s health with a market cap of $14.94 billion, while Boston Scientific, valued at $155.90 billion, offers medical devices for various specialties.

Hologic has shown progress in overcoming challenges, with new strategies in Breast Health and upcoming innovative launches. Diagnostics and GYN Surgical segments show growth potential, supported by a strong balance sheet and strategic acquisitions. However, macroeconomic factors may impact performance.

Boston Scientific closed the first half of 2025 on a strong note, with growth in Cardiovascular and MedSurg segments driven by acquisitions. The company’s Urology and Neuromodulation segments also show promise. While tariff impacts have been reduced, macroeconomic challenges remain.

Hologic shares have dropped 5.4% YTD, while Boston Scientific shares have gained 18.8%. Hologic’s forward price-to-sales ratio is 3.58X, while Boston Scientific’s is 4.14X. Analyst estimates show growth for both companies, with Boston Scientific having a more favorable outlook.

Boston Scientific’s momentum in key segments and acquisitions make it a compelling opportunity, with favorable earnings projections and valuation. Hologic is also on a growth trajectory, but near-term performance may be impacted by economic headwinds. Boston Scientific appears to be the stronger choice.

Boston Scientific (BSX) is ranked #2 (Buy) compared to Hologic (HOLX) at #3 (Hold). For potential high-growth stocks, check out Zacks Investment Research’s top recommendations. Consider these picks for opportunities with significant upside potential.

Read more at Nasdaq: HOLX vs. BSX: Which Healthcare Stock Has More Room to Grow?